Prevalence of prothrombotic polymorphisms in Greece

Genetic Testing

Volumn 12, Issue 4, 2008, Pages 541-547

  Gialeraki, Argyri ^a,b   Politou, Marianna ^a   Rallidis, Loukianos ^a   Merkouri, Efrosyni ^a   Markatos, Christos ^a   Kremastinos, Dimitrios ^a   Travlou, Anthi ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN B; APOLIPOPROTEIN E; BLOOD CLOTTING FACTOR 13; BLOOD CLOTTING FACTOR 5; DIPEPTIDYL CARBOXYPEPTIDASE; FIBRINOGEN; GENOMIC DNA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBOCYTE ANTIGEN;

AFRICAN AMERICAN; ARTICLE; ATHEROSCLEROSIS; CAUCASIAN; CHINESE; DNA PURIFICATION; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GREECE; HUMAN; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION GENETICS; PREVALENCE; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ALLELES; BLOOD COAGULATION FACTORS; COHORT STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GREECE; HUMANS; MALE; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; THROMBOSIS;

EID: 57749121388     PISSN: 10906576     EISSN: None     Source Type: Journal    
DOI: 10.1089/gte.2008.0060     Document Type: Article

References (60)

1. Antoniadi T, Hatzis T, Kroupis C, et al. (1999) Prevalence of factor V Leiden, prothrombin G20210A, and MTHFR C677T mutations in a Greek population of blood donors. Am J Hematol 61:265-267.
2. Bauduer F, Lacombe D (2005) Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab 86:91-99.
3. Bertina RM, Reitsma PH, Rosendaal FR, Vandenbroucke JP (1995) Resistance to activated protein C and factor V Leiden as risk factors for venous thrombosis. Thromb Haemost 74:449-453.
4. Castaman G, Faioni EM, Tosetto A, Bernardi F (2003) The factor V HR2 haplotype and the risk of venous thrombosis: a meta-analysis. Haematologica 88:1182-1189.
5. Chaida C, Gialeraki A, Tsoukala C, Mandalaki T (1996) Prevalence of the FVQ506 mutation in the Hellenic population. Thromb Haemost 76:127.
6. Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 8:1-21.
7. deAngelis MM, Ji F, Kim IK, et al. (2007) Cigarette smoking, CFH, APOE, ELOVL4, and risk of neovascular age-related macular degeneration. Arch Ophthalmol 125:49-54.
8. deGaetano G, Di Castelnuovo A, Donati MB, Iacovello L (2003) The Mediterranean lecture: from epidemiology to physiology and back. Pathophysiol Haemost Thromb 33:466-471.
9. de Visser MC, Guasch JF, Kamphuisen PW, et al. (2000) The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 83:577-582.
10. Donnelly LA, Palmer CN, Whitley AL, et al. (2008) Apolipoprotein E genotypes are associated with lipid-lowering responses to statin treatment in diabetes: a Go-DARTS study. Pharmacogenet Genomics 18:279-287.
11. Emmerich J, Rosendaal FR, Cattaneo M, et al. (2001) Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism - pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 86:809-816.
12. Goldschmidt-Clermont PJ, Cooke GE, Eaton GM, Binkley PF (2000) PlA2, a variant of GPIIIa implicated in coronary thromboembolic complications. J Am Coll Cardiol 36:90-93.
13. Hancer VS, Diz-Kucukkaya R, Bilge AK, et al. (2006) The association between factor XIII Val34Leu polymorphism and early myocardial infarction. Circ J 70:239-242.
14. Hanson NQ, Aras O, Yang F, Tsai MY (2001) C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: incidence and effect of combined genotypes on plasma fasting and post-methionine load homocysteine in vascular disease. Clin Chem 47:661-666.
15. Hoppe B, Tolou F, Dörner T, et al. (2006) Gene polymorphisms implicated in influencing susceptibility to venous and arterial thromboembolism: frequency distribution in a healthy German population. Thromb Haemost 96:465-470.
16. Innerarity TL, Weisgraber KH, Arnold KS, et al. (1987) Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci USA 84:6919-6923.
17. Johannsen P, Jakobsen JK, Jørgensen AL (1997) [Apolipoprotein E genotypes in patients investigated for dementia] Ugeskr Laeger 159:5658-5661.
18. Koch W, Mehilli J, Pfeufer A, et al. (2004) Apolipoprotein E gene polymorphisms and thrombosis and restenosis after coronary artery stenting. J Lipid Res 45:2221-2226.
19. Koumas L, Costeas PA, Papaloizou A, Giantsiou-Kyriakou A (2003) Genetic assessment of cardiovascular risk factors in the Greek Cypriot population. Thromb Res 112:143-146.
20. Kriegshäuser G, Halsall D, Rauscher B, Oberkanins C (2007) Semi-automated, reverse-hybridization detection of multiple mutations causing hereditary fructose intolerance. Mol Cell Probes 21:226-228.
21. Kumar T, Liestøl K, Maehlen J, et al. (2002) Allele frequencies of apolipoprotein E gene polymorphisms in the protein coding region and promoter region (-491A/T) in a healthy Norwegian population. Hum Biol 74:137-142.
22. Lane DA, Grant PJ (2000) Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease. Blood 95:1517-1532.
23. Mahfouz RA, Sabbagh AS, Zahed LF, et al. (2006) Apolipoprotein E gene polymorphism and allele frequencies in the Lebanese population. Mol Biol Rep 33:145-149.
24. Mahfouz RA, Sabbagh AS, Shammaa DM, et al. (2008) Factor XIII gene V34L mutation in the Lebanese population: another unique feature in this community? Mol Biol Rep 35:375-378.
25. Makris TK, Stavroulakis GA, Dafni UG, et al. (2000) ACE/DD genotype is associated with hemostasis balance disturbances reflecting hypercoagulability and endothelial dysfunction in patients with untreated hypertension. Am Heart J 140:760-765.
26. Margaglione M, Bossone A, Coalizzo D, et al. (2002) FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high-risk profile. Thromb Haemost 87:32-36.
27. Marian AJ, Brugada R, Kleiman NS (1996) Platelet glycoprotein IIIa PlA polymorphism and myocardial infarction. N Engl J Med 335:1071-1072.
28. Miserez AR, Laager R, Chiodetti N, Keller U (1994) High prevalence of familial defective apolipoprotein B-100 in Switzerland. J Lipid Res 35:574-583.
29. Philipp CS, Dilley A, Saidi P, et al. (1998) Deletion polymorphism in the angiotensin-converting enzyme gene as a thrombophilic risk factor after hip arthroplasty. Thromb Haemost 80:869-873.
30. Poort SR, Rosendaal FR, Reitsma PH, Bertina (1996) A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 88:3698-3703.
31. Rallidis LS, Gialeraki A, Komporozos C, et al. (2008) Role of methylenetetrahydrofolate reductase 677C- > T polymorphism in the development of premature myocardial infarction. Atherosclerosis 200:115-120.
32. Ray JG, Shmorgun D, Chan WS (2002) Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb 32:51-58.
33. Rees DC (1996) The population genetics of factor V Leiden (Arg506Gln). Br J Haematol 95:579-586.
34. Rees DC, Chapman NH, Webster MT, et al. (1999) Born to clot: the European burden. Br J Haematol 105:564-566.
35. Reitsma PH, Rosendaal FR (2007) Past and future of genetic research in thrombosis. J Thromb Haemost Suppl 1:264-269.
36. Renner W, Köppel H, Hoffmann C, et al. (2000) Prothrombin G20210A, factor V Leiden, and factor XIII Val34Leu: common mutations of blood coagulation factors and deep vein thrombosis in Austria. Thromb Res 99:35-39.
37. Renner W, Cichocki L, Forjanics A, et al. (2002) G-455A polymorphism of the fibrinogen beta gene and deep vein thrombosis. Eur J Clin Invest 32:755-758.
38. Ridker PM, Hennekens CH, Schmitz C, et al. (1997) PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction stroke, and venous thrombosis. Lancet 349:385-388.
39. Rigat B, Hubert C, Alhenc-Gelas F, et al. (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343-1346.
40. Rosendaal FR (1999) Venous thrombosis: prevalence and interaction of risk factors. Haemostasis Suppl S1:1-9.
41. Rosendaal FR, Doggen CJ, Zivelin A, et al. (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79:706-708.
42. Rozman P (2002) Platelet antigens. The role of human platelet alloantigens (HPA) in blood transfusion and transplantation. Transpl Immunol 10:165-181.
43. Sabbagh AS, Ibrahim G, Kanaan Z, et al. (2006) Prevalence of factor V R2 (H1299R) polymorphism in the Lebanese population. Pathology 38:442-444.
44. Sabbagh AS, Daher RT, Otrock ZK, et al. (2007a) ApoB-100 R3500Q mutation in the Lebanese population: prevalence and historical review of the literature. Mol Biol Rep 34:267-270.
45. Sabbagh AS, Otrock ZK, Mahfoud ZR, et al. (2007b) Angiotensin-converting enzyme gene polymorphism and allele frequencies in the Lebanese population: prevalence and review of the literature. Mol Biol Rep 34:47-52.
46. Sabbagh AS, Taher AT, Zaatari GS, et al. (2007c) Gene frequencies of the HPA-1 platelet antigen alleles in the Lebanese population. Transfus Med 17:473-478.
47. Sabbagh AS, Ibrahim G, Kanaan Z, et al. (2007) Prevalence of the prothrombin G20210A polymorphism in the Lebanese population: use of a reverse hybridisation strip assay approach. Mol Biol Rep [Epub ahead of print].
48. Sabbagh AS, Mahfoud Z, Taher A, et al. (2008) High prevalence of MTHFR Gene A1298C Polymorphism in Lebanon. Genet Test 12:75-80.
49. Sazci A, Ergul E, Kaya G, Kara I (2005) Genotype and allele frequencies of the polymorphic methylenetetrahydrofolate reductase gene in Turkey. Cell Biochem Funct 23:51-54.
50. Seligsohn U, Lubetsky A (2001) Genetic susceptibility to venous thrombosis. N Engl J Med 344:1222-1231.
51. Seripa D, Gravina C, Volpe R, et al. (1999) Absence of apolipoprotein B3500 mutation in type 2a hyperlipoproteinemia patients and in the general population from southern Italy. J Inherit Metab Dis 22:670-671.
52. Shammaa DM, Sabbagh AS, Taher AT, et al. (2008) Frequency distribution of the G/A alleles of the beta-fibrinogen gene in the Lebanese population. Mol Biol Rep 35:453-457.
53. Stegnar M, Uhrin P, Peternel P, et al. (1998) The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 79:975-979.
54. Stein PD, Kayali F, Olson RE, Milford CE (2004) Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census. Am J Med 116:435-442.
55. Tsantes AE, Nikolopoulos GK, Bagos PG, et al. (2008) The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk. Thromb Res 122:736-742.
56. van Horn L, McCoin M, Kris-Etherton PM, et al. (2008) The evidence for dietary prevention and treatment of cardiovascular disease. J Am Diet Assoc 108:287-331.
57. Weger M, Renner W, Steinbrugger I, et al. (2005) Role of thrombophilic gene polymorphisms in branch retinal vein occlusion. Ophthalmology 112:1910-1915.
58. Wells PS, Anderson JL, Scarvelis DK, et al. (2006) Factor XIII Val34Leu variant is protective against venous thromboembolism: a HuGE review and meta-analysis. Am J Epidemiol 164:101-109.
59. Yi P, Pogribny I, Jill James S (2002) Multiplex PCR for simultaneous detection of 677 C - > T and 1298 A - > C polymorphisms in methylenetetrahydrofolate reductase gene for population studies of cancer risk. Cancer Lett 181:209-213.
60. Zaatari GS, Otrock ZK, Sabbagh AS, Mahfouz RA (2006) Prevalence of factor VR2(H1299R) polymorphism in the Lebanese population. Pathology 38:442-444.